30 closest matches · ranked by relevance
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants
Oncology · Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 DLTs
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
AML
Primary: Complete Response Rate — 19 Participants
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 45 participants
Leukemia · Myelodysplastic Syndromes · Blastic Plasmacytoid Dendritic Cell Neoplasm
Primary: Overall Response Rate (CR+PR+SD): Percentage of Participants Experiencing Response — 81.8 percentage of participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
Acute Leukemia of Ambiguous Lineage · B Acute Lymphoblastic Leukemia · Mixed Phenotype Acute Leukemia
Primary: Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement…
Acute Myeloid Leukemia
Primary: Response Rate of Crenolanib Besylate Combination Therapy — 2; 0; 3; 1 Participants
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL · Leukemia Cutis · Recurrent Acute Myeloid Leukemia
Primary: Incidence of Dose-limiting Toxicities (DLTs) (Phase Ib)
Acute Myeloid Leukemia
Primary: Part 1 and Part 2: Number of Participants Experiencing Treatment-emergent Adverse Events — 2; 3; 3; 6 Participants
Leukemia
Primary: Participants With a Response CR + PR + CRi — 4; 1; 4 Participants
Acute Myeloid Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) at Phase 1B — 0; 0; 0; 0 Participants
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Primary: Maximum Tolerated Dose of 5-azacytidine in the Combination of Nivolumab With Dihydro-5-azacytidine — 75; 75; 75 Mg/m^2
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Leukemia, Acute Myeloid (AML)
Primary: Duration of Overall Survival (OS) — 9.3; 5.6 Months — p=0.0004
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 2 Participants
Acute Myeloid Leukemia
Primary: Number of Participants With Complete Remission With or Without Incomplete Platelet Recovery — 1 Participants
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Leukemia
Primary: Dose-limiting Toxicity — 0; 0 participants
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Overall Survival (OS) — 9.82; 9.23; 5.24 months — p=0.523
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 24; 29 participants